# An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

> **NCT00524043** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 201 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone ER
- **DRUG:** Placebo
- **DRUG:** Paliperidone ER

## Key facts

- **NCT ID:** NCT00524043
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2014-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00524043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00524043, "An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00524043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*